BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21609928)

  • 1. Safe use of FOLFOX in two patients with metastatic colorectal carcinoma and severe hepatic dysfunction.
    Roderburg C; do O N; Fuchs R; Bubenzer J; Spannbauer M; Luedde T; Trautwein C; Tischendorf JJ
    Clin Colorectal Cancer; 2011 Mar; 10(1):E6-9. PubMed ID: 21609928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severe liver dysfunction and safe use of 5-fluorouracil leucovorin and oxaliplatin in one patient with metastatic colorectal carcinoma.
    Tural D; Akar E; Öztürk MA; Yıldız Ö; Turna H; Serdengeçti S
    J Cancer Res Ther; 2014; 10(3):745-8. PubMed ID: 25313774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
    Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer.
    Kemeny N; Jarnagin W; Paty P; Gönen M; Schwartz L; Morse M; Leonard G; D'Angelica M; DeMatteo R; Blumgart L; Fong Y
    J Clin Oncol; 2005 Aug; 23(22):4888-96. PubMed ID: 16009951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of hepatic arterial infusion therapy and FOLFOX for colorectal cancer with multiple unresectable liver metastases causing severe liver dysfunction].
    Suto T; Sato T; Mori N; Takano N; Ishiyama K; Sakurai N; Saito K; Iizawa H; Ikeda E
    Gan To Kagaku Ryoho; 2009 Jan; 36(1):71-6. PubMed ID: 19151566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
    Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
    Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial infusion chemotherapy using fluorouracil followed by systemic therapy using oxaliplatin plus fluorouracil and leucovorin for patients with unresectable liver metastases from colorectal cancer.
    Seki H; Ozaki T; Shiina M
    Cardiovasc Intervent Radiol; 2009 Jul; 32(4):679-86. PubMed ID: 19296157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of FOLFOX followed by cetuximab for metastatic colorectal cancer with severe liver dysfunction.
    Elsoueidi R; Craig J; Mourad H; Richa EM
    J Natl Compr Canc Netw; 2014 Feb; 12(2):155-60. PubMed ID: 24586077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.
    Rothenberg ML; Oza AM; Bigelow RH; Berlin JD; Marshall JL; Ramanathan RK; Hart LL; Gupta S; Garay CA; Burger BG; Le Bail N; Haller DG
    J Clin Oncol; 2003 Jun; 21(11):2059-69. PubMed ID: 12775730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-fluorouracil leucovorin and oxaliplatin (FOLFOX) in the treatment of metastatic colon cancer with severe liver dysfunction.
    Fakih MG
    Oncology; 2004; 67(3-4):222-4. PubMed ID: 15557782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adjuvant chemotherapy with FOLFOX4 regimen after curative resection of liver metastases from colorectal cancer].
    Ohnishi T; Kanoh T; Tono T; Danno K; Watanabe A; Nakamura H; Tsukao Y; Inatome J; Kim T; Kagara N; Taniguchi H; Kimura Y; Nakano Y; Monden T; Imaoka S
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2554-6. PubMed ID: 21224637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
    Grenader T; Goldberg A; Gabizon A
    Anticancer Drugs; 2009 Oct; 20(9):845-7. PubMed ID: 19633535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
    Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
    Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folfox4 regimen administered through combined hepatic arterial and systemic infusion for treatment of colorectal cancer with unresectable liver metastases.
    Guan M; Chen SC; Ying HY; Zhao L; Li XY; Zhou JF; Shao YJ; Yang XD; Lin Y; Ning XH; Bai CM
    Chin Med J (Engl); 2012 Oct; 125(20):3640-5. PubMed ID: 23075717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy.
    Shimura T; Kataoka H; Hirata Y; Mizushima T; Murakami K; Mabuchi M; Mizoshita T; Kubota E; Tanida S; Kamiya T; Joh T
    J Gastrointest Cancer; 2011 Mar; 42(1):68-72. PubMed ID: 20563895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
    Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
    N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer.
    Ducreux M; Ychou M; Laplanche A; Gamelin E; Lasser P; Husseini F; Quenet F; Viret F; Jacob JH; Boige V; Elias D; Delperro JR; Luboinski M;
    J Clin Oncol; 2005 Aug; 23(22):4881-7. PubMed ID: 16009952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.